IRCT20190504043465N1 IRCT 2019-05-18 Pooyesh Darou Efficacy and safety of PDlasta® and PDgrastim® in breast cancer Comparison of PDlasta® (Pegfilgrastim) & PDgrastim® (Filgrastim) efficacy and safety in increasing absolute neutrophil count in breast cancer patients on adjuvant and neoadjuvant treatment with Dose-dense ac4-t4 2016-09-15 anticipated 80 Complete https://irct.ir/trial/39264 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: For random allocation of participants into two arm of treatments, the permuted block randomization was used with quadruple blocks. According to the identified sample size of 80, twenty blocks were produced. Four persons of each group were randomly and equally assigned to treatment A or B using a toss. In order to apply the concealment in the randomization process, 20 thick pocket were selected randomly by the software (www.sealedenvelope.com). By this method, nobody was aware of allocation sequence of participants to treatment groups, Blinding description: Due to the different protocol of prescribing two drugs and the necessity of monitoring an oncologist, there is no possibility of blinding the patient and the therapist. The results analyst specialist will not be informed about how people are assigned to groups. 3 Breast cancer. Intervention 1: Intervention group: Patients receive the subcutaneous injection of 6 mg of Pegfilgrastim (PDlasta) in each chemotherapy cycle (on the first day after chemotherapy (24 hours later). Intervention 2: Control group: Patients on the first day after chemotherapy (24 hours later) will use Filgrastim (PDgrastim) for subcutaneous injection of 300 micrograms daily for six consecutive days. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information.